Cbl (Ab 700) Antilichaam

Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.

867

P22681

NP_005179.2

Human

C-Cbl (Ab-700) antibody was raised against a peptide sequence around aa. 698~702 (T-E-Y-M-T) derived from Human c-Cbl.

Unconjugated

Primary Antibodies

Apoptosis, Cancer

Antibodies were purified by affinity-chromatography using epitope-specific peptide.

1 mg/mL

Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

None

Blue Ice

Store antibody at -20˚ C for up to one year.

120 kDa

This antibody detects endogenous level of total c-Cbl protein.

Western Blot: 1:500~1:1000, Immunohistochemistry: 1:50~1:100

CBL

Cbl proto-oncogene, E3 ubiquitin protein ligase

Homo sapiens

Blake, T. J. et al. (1991) Oncogene 6, 653-657. Thien, C. B. and Langdon, W. Y. (1998) Immunol. Cell Biol. 76, 473-482. Kamei, T. et al. (2000) Int. J. Oncol. 17, 335-339. Hunter, C. et al. (1999) J. Biol. Chem. 274, 2097-2106.

CBL2, NSLL, C-CBL, RNF55, FRA11B, CSDD2, Signal transduction protein CBL, Proto-oncogene c-CBL, Casitas B-lineage lymphoma proto-oncogene, RING finger protein 55

WB, IHC

52426745

Liquid